16:00 Mar 5, 2002 |
English to Hungarian translations [PRO] Medical | |||||||
---|---|---|---|---|---|---|---|
|
| ||||||
| Selected response from: Attila Piróth France Local time: 19:52 | ||||||
Grading comment
|
Summary of answers provided | ||||
---|---|---|---|---|
4 | fejlesztés alatt álló hatóanyag/gyógyszer |
|
fejlesztés alatt álló hatóanyag/gyógyszer Explanation: Az alábbi részből szerintem kitetszik, hogy miről van szó: egy fejlesztés alatt álló hatóanyagról (ágensről), melyet a gyógyszer forgalmazása előtt több betegcsoporton kipróbálnak. Product Candidate: IDEC-152 (anti-CD23) IDEC-152 has the potential to decrease the body's response to allergens, thereby affecting diseases related to asthma and allergic disorders. IDEC's monoclonal antibody binds to the CD23 receptor. By binding to this receptor, IDEC-152 may favorably influence asthma through its selective regulation of IgE production and its inhibition of other inflammatory pathways. Clinical Trial Update In March 2001 at the 57th Annual Meeting of the American Academy of Allergy, Asthma and Immunology in New Orleans. IDEC announced results from a single-dose, placebo-controlled, dose-escalating Phase I trial of its investigational agent IDEC-152, a PRIMATIZEDŽ anti-CD23 monoclonal antibody in patients with allergic asthma. Reference: http://www.idecpharm.com/site/science/idec152.htm |
| |
Grading comment
| ||
Login to enter a peer comment (or grade) |
Login or register (free and only takes a few minutes) to participate in this question.
You will also have access to many other tools and opportunities designed for those who have language-related jobs (or are passionate about them). Participation is free and the site has a strict confidentiality policy.